<DOC>
	<DOCNO>NCT02349022</DOCNO>
	<brief_summary>The purpose study compare diagnostic performance [ 89Zr ] -Df-IAB2M PET/CT [ 111In ] -capromab pendetide immuno PET tracer detection prostate cancer pre-prostatectomy confirm pathology . Individuals participate study [ 111In ] -capromab pendetide scan , well PET scan follow injection [ 89Zr ] -Df-IAB2M .</brief_summary>
	<brief_title>Comparison PET With 89Zr-Df-IAb2M 111In-Capromab Pendetide Detection Prostate Cancer Pre-Prostatectomy</brief_title>
	<detailed_description>IAB2M approximately 80 kDA molecular weight antibody fragment ( `` Minibody '' ) chelate Desferroxamine radiolabeled 89Zr . [ 89Zr ] -Df-IAB2M target extracellular domain Prostate Membrane Specific Antigen ( PSMA ) express primary metastatic prostate cancer lesion . [ 111In ] -capromab pendetide ( Prostascint® ) FDA approve imaging agent target intracellular domain PSMA . It anticipate [ 89Zr ] -Df-IAB2M outperform Prostascint® target difference .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients must meet ALL criterion list entry : Age ≥ 18 year Signed , write IRBapproved informed consent Patients newly diagnose biopsyproven prostate cancer , think candidate prostatectomy standard diagnostic evaluation ( e.g . chest xray , CT scan MRI ) highrisk pelvic lymph node metastasis . High Risk define : Gleason score ≥ 8 Gleason 4+3 PSA &gt; 10 PSA &gt; 20 ng/mL T3a Patients schedule [ 111In ] capromab pendetide scan recent [ 111In ] capromab pendetide scan within 28 day screen visit would willing undergo [ 111In ] capromab pendetide scan Karnofsky Performance status ≥ 60 Life expectancy least 6 month Patients previous history another malignancy ( insitu cancer , basal squamous cell skin cancer ) must disease free period three year . Acceptable liver function : Bilirubin ≤ 1.5 time upper limit normal &lt; 3 x ULN patient Gilbert 's disease AST ( SGOT ) , ALT ( SGPT ) Alkaline phosphatase ≤ 2.5 time upper limit normal ( liver metastasis present , ≤ 5 x ULN allow ) Acceptable renal function : Serum creatinine within normal limit , OR calculate creatinine clearance ≥ 60 mL/min/1.73 m2 patient creatinine level institutional normal . Acceptable hematologic status : Granulocyte ≥ 1500 cells/mm3 Platelet count ≥ 150,000 ( plt/mm3 ) Hemoglobin ≥ 9 g/dL For men childproducing potential , use effective contraceptive method study Patients exclude entry ANY criterion list meet : New York Heart Association Class III IV , cardiac disease , myocardial infarction within past 6 month Unstable arrhythmia , evidence ischemia ECG Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Treatment radiation therapy , surgery , chemotherapy , investigational therapy prostate cancer . Unwillingness inability comply procedure require protocol Known infection HIV , hepatitis B , hepatitis C Serious nonmalignant disease ( eg , hydronephrosis , liver failure , condition ) could compromise protocol objective opinion investigator and/or sponsor Previous [ 111In ] capromab pendetide image test</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>[ 89Zr ] Df-IAB2M</keyword>
	<keyword>Prostate cancer</keyword>
	<keyword>PET scan</keyword>
</DOC>